Singh CRISPR-Cas-Based Genome Editing for Treating Human Diseases - Part B

1. Auflage 2025
ISBN: 978-0-443-22421-8
Verlag: Elsevier Science & Techn.
Format: EPUB
Kopierschutz: 6 - ePub Watermark

E-Book, Englisch, Band Volume 210, 300 Seiten

Reihe: Progress in Molecular Biology and Translational Science

CRISPR-Cas-Based Genome Editing for Treating Human Diseases, Part B represents CRISPR-Cas systems for genome editing. Currently, CRISPR-Cas systems have been proven to be a key technology for targeted genome editing, which is acting as a simple, rapid, and cost-effective solution. Chapters in this release include Current approaches in CRISPR -Cas systems for metabolic disorders, Recent progress in CRISPR -Cas systems for CRISPR for retinal diseases, Recent progress in CRISPR -Cas systems for cataract and blindness, Advances in CRISPR -Cas systems for muscular dystrophy, Recent development in CRISPR -Cas systems for cardiac disease, Current approaches in CRISPR -Cas systems for diabetes, and much more.Additional sections cover Advances in CRISPR -Cas systems for liver disease, Advances in CRISPR -Cas systems for lung disease, Advances in CRISPR -Cas systems for kidney diseases, Current progress in CRISPR -Cas systems for rare disease, Advances in CRISPR -Cas systems for heredity disease, Recent progress in CRISPR -Cas systems for neurological disorders, and CRISPR challenges in clinical developments. - Provides CRISPR-Cas systems for metabolic disorders, retinal disease cataracts, and blindness - Offer updates on muscular dystrophy, cardiac disease, diabetes, and liver disease - Includes content on lung disease, kidney diseases, rare diseases, heredity diseases, neurological disorders, and CRISPR challenges in clinical developments

Autoren/Hrsg.

Singh, Vijai